196 related articles for article (PubMed ID: 28928900)
1. Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Dorasamy MS; Choudhary B; Nellore K; Subramanya H; Wong PF
J Cancer; 2017; 8(15):3086-3098. PubMed ID: 28928900
[TBL] [Abstract][Full Text] [Related]
2. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
3. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
4. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
5. Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma.
Liu L; Dong Z; Lei Q; Yang J; Hu H; Li Q; Ji Y; Guo L; Zhang Y; Liu Y; Cui H
Oncotarget; 2017 Dec; 8(68):112354-112370. PubMed ID: 29348830
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
8. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
9. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation.
Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK
bioRxiv; 2024 Jan; ():. PubMed ID: 37066260
[TBL] [Abstract][Full Text] [Related]
10. DHODH Inhibition Exerts Synergistic Therapeutic Effect with Cisplatin to Induce Ferroptosis in Cervical Cancer through Regulating mTOR Pathway.
Jiang M; Song Y; Liu H; Jin Y; Li R; Zhu X
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672495
[TBL] [Abstract][Full Text] [Related]
11. DHODH and cancer: promising prospects to be explored.
Zhou Y; Tao L; Zhou X; Zuo Z; Gong J; Liu X; Zhou Y; Liu C; Sang N; Liu H; Zou J; Gou K; Yang X; Zhao Y
Cancer Metab; 2021 May; 9(1):22. PubMed ID: 33971967
[TBL] [Abstract][Full Text] [Related]
12. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
[TBL] [Abstract][Full Text] [Related]
13. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
Boschi D; Pippione AC; Sainas S; Lolli ML
Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612
[TBL] [Abstract][Full Text] [Related]
14.
Zhao E; Jiang X; Cui H
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200251
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.
Dorasamy MS; Ab A; Nellore K; Wong PF
Biomed Pharmacother; 2019 Feb; 110():29-36. PubMed ID: 30458345
[TBL] [Abstract][Full Text] [Related]
16. DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma.
Olsen TK; Dyberg C; Embaie BT; Alchahin A; Milosevic J; Ding J; Otte J; Tümmler C; Hed Myrberg I; Westerhout EM; Koster J; Versteeg R; Ding HF; Kogner P; Johnsen JI; Sykes DB; Baryawno N
JCI Insight; 2022 Aug; 7(17):. PubMed ID: 35943801
[TBL] [Abstract][Full Text] [Related]
17. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression.
Hai Y; Fan R; Zhao T; Lin R; Zhuang J; Deng A; Meng S; Hou Z; Wei G
Pharmacol Res; 2024 Apr; 202():107115. PubMed ID: 38423231
[TBL] [Abstract][Full Text] [Related]
18. Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells.
Eriksen-Gjerstad M; Tveit Karlsen I; Fandalyuk Z; Benjaminsen S; Baran-Marszak F; Papp B; Locke F; Ladds M; Pastor-Fernández A; Gelebart P; Mc Cormack E
EJHaem; 2022 Aug; 3(3):913-918. PubMed ID: 36051066
[TBL] [Abstract][Full Text] [Related]
19. Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling.
Kawatani M; Aono H; Hiranuma S; Shimizu T; Muroi M; Nogawa T; Ohishi T; Ohba SI; Kawada M; Yamazaki K; Dan S; Dohmae N; Osada H
Oncol Res; 2023; 31(6):833-844. PubMed ID: 37744270
[TBL] [Abstract][Full Text] [Related]
20. Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.
Gwynne WD; Suk Y; Custers S; Mikolajewicz N; Chan JK; Zador Z; Chafe SC; Zhai K; Escudero L; Zhang C; Zaslaver O; Chokshi C; Shaikh MV; Bakhshinyan D; Burns I; Chaudhry I; Nachmani O; Mobilio D; Maich WT; Mero P; Brown KR; Quaile AT; Venugopal C; Moffat J; Montenegro-Burke JR; Singh SK
Cancer Cell; 2022 Dec; 40(12):1488-1502.e7. PubMed ID: 36368321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
